Danske Bank A S Sells 34,176 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Danske Bank A S lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 31.7% in the third quarter, HoldingsChannel reports. The firm owned 73,654 shares of the biopharmaceutical company’s stock after selling 34,176 shares during the quarter. Danske Bank A S’s holdings in Regeneron Pharmaceuticals were worth $55,850,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in REGN. Diversified Trust Co boosted its holdings in shares of Regeneron Pharmaceuticals by 7.8% during the third quarter. Diversified Trust Co now owns 2,675 shares of the biopharmaceutical company’s stock valued at $2,028,000 after acquiring an additional 194 shares during the period. Aberdeen Group plc grew its position in shares of Regeneron Pharmaceuticals by 560.7% during the third quarter. Aberdeen Group plc now owns 671,042 shares of the biopharmaceutical company’s stock worth $508,831,000 after acquiring an additional 569,476 shares during the last quarter. Moors & Cabot Inc. grew its position in shares of Regeneron Pharmaceuticals by 13.0% during the third quarter. Moors & Cabot Inc. now owns 729 shares of the biopharmaceutical company’s stock worth $553,000 after acquiring an additional 84 shares during the last quarter. Allworth Financial LP increased its holdings in shares of Regeneron Pharmaceuticals by 4.5% in the 3rd quarter. Allworth Financial LP now owns 2,644 shares of the biopharmaceutical company’s stock worth $2,005,000 after acquiring an additional 114 shares during the period. Finally, Fisher Asset Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth about $264,000. 83.31% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Kathryn Guarini sold 400 shares of the firm’s stock in a transaction that occurred on Friday, October 30th. The shares were sold at an average price of $900.00, for a total transaction of $360,000.00. Following the transaction, the director owned 603 shares in the company, valued at $542,700. This trade represents a 39.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christine A. Poon sold 7,830 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $969.09, for a total value of $7,587,974.70. Following the sale, the director directly owned 5,219 shares in the company, valued at approximately $5,057,680.71. The trade was a 60.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 27,028 shares of company stock worth $25,025,950. Company insiders own 6.97% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on REGN. JPMorgan Chase & Co. lifted their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $1,050.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Raymond James Financial upped their target price on shares of Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. HSBC upped their target price on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Wells Fargo & Company raised their price target on shares of Regeneron Pharmaceuticals from $750.00 to $925.00 and gave the company an “equal weight” rating in a research note on Monday, November 2nd. Finally, Evercore lifted their price target on Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the company an “outperform” rating in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $898.97.

Get Our Latest Report on REGN

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $955.47 on Monday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $591.52 and a 1 year high of $991.73. The stock has a market cap of $98.84 billion, a price-to-earnings ratio of 21.10, a PEG ratio of 1.26 and a beta of 0.10. The business has a fifty day moving average of $816.17 and a 200-day moving average of $747.36. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.35.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last issued its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The company had revenue of $5.12 billion for the quarter, compared to analyst estimates of $4.58 billion. During the same period last year, the company earned $11.83 earnings per share. The company’s quarterly revenue was up 36.3% compared to the same quarter last year. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 58.26 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 3rd. Stockholders of record on Friday, November 20th will be paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Friday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.30%.

Regeneron Pharmaceuticals Profile

(Free Report)

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

Featured Articles

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.